FDA approves injectable version of Bristol Myers Squibb's cancer drug Opdivo (Dec. 27)
By Sneha S K and Sriparna Roy (Reuters) -The U.S. Food and Drug Administration said on Friday that it has approved an ...
FDA approves injectable version of Bristol Myers Squibb's cancer drug Opdivo
By Sneha S K and Sriparna Roy (Reuters) - The U.S. Food and Drug Administration said on Friday that it has approved an ...
Bristol Myers Squibb Co. stock underperforms Tuesday when compared to competitors despite daily gains
This was the stock's second consecutive day of gains.
Novo Nordisk expands AI partnership with Valo Health for development of obesity drugs
Danish drugmaker Novo Nordisk and U.S. tech firm Valo Health said on Wednesday they were expanding their 2023 agreement to ...
Study identifies risk potential for thousands of mutations of a cancer gene
Scientists have characterized the role of thousands of mutations in the BRCA2 cancer gene, findings that may help reassure ...
The T1D Fund Appoints Industry Veteran Elizabeth Mily as CEO to Accelerate Development of Type 1 Diabetes Cures Through Impact Investing
The T1D Fund, an impact investment fund with a focus on accelerating life-changing solutions to treat, prevent, and cure type ...
BioSpace9h
Pharmas Turn to Licensing Deals as Risky Science Rises
Licensing deals have risen in prominence in a restrained market environment. Is it desperation, or an important part of the ...
Cambridge Cognition product used in schizophrenia treatment trial
Cambridge Cognition announced the use of its ‘CANTAB’ cognitive assessment product in two phase three clinical trials conducted by Bristol Myers Squibb for ‘Cobenfy’, a newly FDA-approved treatment ...
MPM BioImpact Appoints Brian Shuster, Experienced in Healthcare Corporate Development, as Entrepreneur Partner
MPM BioImpact, a biotechnology investment firm creating and investing in innovative companies seeking to deliver ...
BioSpace23h
CytomX to Cut 40% of Staff as It Updates Pipeline Priorities
CytomX’s workforce cuts could leave the biotech with fewer than 75 employees as it focuses resources on its wholly owned ...
manilatimes2h
Aer Therapeutics Announces First Patient Dosed in Phase 2 Clinical Trial of Fexlamose in Chronic Obstructive Pulmonary Disease
Fexlamose is being developed as a chronic treatment for COPD and asthma in conjunction with standard therapies, to improve ...
FierceBiotech4h
LB Pharma's twist on old Sanofi drug passes schizophrenia test, teeing up phase 3 push
Bristol Myers Squibb’s Cobenfy achieved an 8.4-point PANSS improvement over placebo after five weeks in a phase 3 trial that ...